Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17 USD | -2.52% | +37.08% | +55.36% |
Sales 2024 * | - | Sales 2025 * | 1.6M 127M | Capitalization | 650M 51.73B |
---|---|---|---|---|---|
Net income 2024 * | -158M -12.58B | Net income 2025 * | -241M -19.18B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 406 x |
P/E ratio 2024 * |
-4.27
x | P/E ratio 2025 * |
-2.91
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.29% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | -2.55% | ||
1 week | +37.08% | ||
Current month | +58.40% | ||
1 month | +44.66% | ||
3 months | +68.94% | ||
6 months | +77.21% | ||
Current year | +55.36% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 31/03/12 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 31/05/20 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 30/04/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 31/05/20 |
David Hallal
CHM | Chairman | 57 | 31/05/18 |
Director/Board Member | 52 | 31/05/18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 28 M€ | -0.82% |
Date | Price | Change | Volume |
---|---|---|---|
13/05/24 | 17 | -2.49% | 183 067 |
10/05/24 | 17.44 | +43.07% | 5,259,062 |
09/05/24 | 12.19 | -0.08% | 84,546 |
08/05/24 | 12.2 | -0.89% | 146,984 |
07/05/24 | 12.31 | -0.81% | 296,759 |
Delayed Quote Nasdaq, May 13, 2024 at 03:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.36% | 650M | |
+4.93% | 109B | |
+11.63% | 105B | |
+0.41% | 22.25B | |
-11.63% | 22.09B | |
-7.82% | 18.68B | |
-38.36% | 17.58B | |
-9.26% | 16.85B | |
+4.74% | 13.76B | |
+37.10% | 12.46B |
- Stock Market
- Equities
- ITOS Stock